The observed decrease in pro-oncogenic miR21, hypoxia related and pro-oncogenic miR210 and the increase in anti-oncogenic miR126 levels in GBM cell-derived EVs, caused by the different PAD isozyme-specific inhibitors in the current study, indicates GBM cell type selective anti-GBM functions of the different PAD isozyme-specific inhibitors. This evidence concerns the gene PADI4 and glioblastoma.